SCHEMBL6340401

SCHEMBL6340401

CCCCN(C1CCCCc2ccc(F)cc21)S(=O)(=O)CC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.35
HTR6 P50406 1/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
METAP2 P50579 4/20 0.34
KCNE1 P15382 3/20 0.33
KCNQ1 P51787 3/20 0.33
BCHE P06276 2/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6557938 0.83 BCHE (0.46) BCHEPDE4APDE4BPDE4CPDE4D
SCHEMBL6347944 0.83 KCNE1 (0.43) HTR6PSEN1PSEN2APH1BNCSTN
SCHEMBL8181427 0.79 HTT (0.48) BCHEPDE4APDE4BPDE4CPDE4D
SCHEMBL6558637 0.77 KCNE1 (0.40) RORCKCNE1KCNQ1
SCHEMBL6558722 0.70 KCNE1 (0.48) KCNE1KCNQ1
SCHEMBL6340312 0.69 CYP11B1 (0.40) HTR2AHTR2C
SCHEMBL8180505 0.68 CYP19A1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL19658420 0.67 ALDH1A1 (0.48) HTR6HTR2AHTR2CTMEM97SIGMAR1
SCHEMBL6338888 0.67 SLC6A2 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13198415 0.66 HTR2A (0.58) HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908947-B2 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-21 US disclosed
EP-0861836-B1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity AVENTIS PHARMA GMBH (DE) 2004-12-29 EP disclosed
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them HOECHST AKTIENGESELLSCHAFT 2002-06-13 US disclosed
US-6333349-B1 POTASSIUM CHANNEL OR THE I.SUB.KS CHANNEL OPENED BY CYCLIC ADENOSINE MONOPHOSPHATE AS POTASSIUM CHANNEL ACTIVATORS AND CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL REGION OR FOR THE TREATMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-25 US disclosed
EP-0861836-A1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them KCNN3, KCNJ1, KCNJ11 RORC 2376/4885HTR6 2337/4885PSEN1 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.